Mersin Üniversitesi

Running trials

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Eli Lilly and Company· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

  NCT06699849· Phase 2· CSL Behring· Source

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Effect of Dual-Task Training and Cognitive Rehabilitation in Individuals With Multiple Sclerosis.

  NCT06949696· Toros University· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

  NCT07159750· Hospital Universitari Vall d'Hebron Research Institute· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

  NCT04975308· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

  NCT04603495· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

  NCT04232553· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

  NCT03519945· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ulcerative colitis3 recruiting
• Obesity2 recruiting
• Crohn's disease1 recruiting
• Migraine1 recruiting
• Multiple sclerosis1 recruiting
• Sickle cell disease1 recruiting

Closed trials

• Completed

  The Effect of Intrarectal Ice Application on Pain, Anxiety, Cortisol Level, Complication Development in Transrectal Ultrasonography Guided Prostate Biopsy

  NCT06998121· Mersin University· Source

• Completed

  Head Awareness in Chronic Migraine Patients

  NCT06857383· Bozok University· Source

• Completed

  Tampa Kinesiophobia Scale Modified for Headache

  NCT06857357· Bozok University· Source

• Completed

  Osteoporosis Awareness Among Nursing Students

  NCT06760780· Mersin University· Source

• Completed

  Preoperative Sarcopenia and Surgical Outcomes in Colorectal Cancer Patients

  NCT06698289· Mersin University· Source

• Completed

  Effects of Information-Motivation-Behavioral Skills Model on Disease Management of Adolescents With Epilepsy

  NCT06045520· Mersin University· Source

• Completed

  EMDR on Pain in Patients With in Patients Rheumatoid Arthritis

  NCT05944302· Mersin University· Source

• Completed

  A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

  NCT05803421· Phase 3· Eli Lilly and Company· Source

• Terminated

  A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

  NCT05592275· Phase 2· Eli Lilly and Company· Source

• Completed

  Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis

  NCT05706870· Phase 2· GEN İlaç ve Sağlık Ürünleri A.Ş.· Source

• Completed

  Sarcopenia in Patients With Idiopathic Pulmonary Fibrosis

  NCT07178197· Mersin University· Source

• Completed

  A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

  NCT05093933· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  The Evaluation of White Matter Intensities in Patients with Pediatric Epilepsy

  NCT06887504· Aysen Orman· Source

• Completed

  Uric Acid Levels and Migraine in Children

  NCT06966037· Aysen Orman· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Migraine32 works · 4 trials
• IgA nephropathy5 works · 0 trials